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Abstract
Background The use of fully covered metal stents (FCSEMS) and specifically designed lumen apposing metal stents for 
transmural drainage of pancreatic fluid collections has become widespread. A systematic review published in 2015 did not 
support the routine use of metal stents for drainage of pancreatic fluid collections. However, recent studies have shown 
conflicting data; therefore a systematic review and meta-analysis was performed.
Method We conducted a database search for original comparative studies between plastic and metal stents. The random 
effects model was used to calculate pooled risk ratios (RR) with 95% confidence intervals (CI). Outcomes analysed were 
clinical success, adverse events and requirement of further intervention.
Results The search identified 936 studies, 7 studies with 681 (340 metal, 341 plastic) patients met inclusion criteria and 
were included in the meta-analysis. Clinical success was achieved in 93.8% versus 86.2% in the metal and plastic groups, 
respectively, RR 1.08 [95% CI 1.02–1.14]; p = 0.009. Adverse events were reduced for metal stents when compared with 
plastic (10.2% vs. 25.0%), RR 0.42 [95% CI 0.22–0.81]; p = 0.010. Metal stent usage reduced bleeding (2.8% vs. 7.9%), RR 
0.37; [95% CI 0.18–0.75]; p = 0.006. Further intervention was required in 12.4% of patients in the metal stent group versus 
26.7% for plastic stents, RR 0.54; [95% CI 0.22–1.29]; p = 0.165.
Conclusions The use of metal stents for drainage of pancreatic fluid collections is associated with improved clinical success, 
fewer adverse events and reduced bleeding compared to plastic stents.
Keywords Pancreatic fluid collection · Metal stents · Plastic stents · Endoscopic ultrasound intervention · Pancreatic 
pseudocyst · Drainage
Pancreatic and peri-pancreatic fluid collections (PFC) are 
common following an insult to the pancreas [1, 2]. It is 
important to differentiate between those, which are purely 
fluid, and those that contain necrotic tissue when considering 
appropriate treatments. The revised Atlanta Classification 
states that acute peri-pancreatic fluid collections (APFC) 
are homogenous, do not have a well-defined wall and can be 
multiple. They occur within the first 4 weeks of non-necrotic 
interstitial oedematous pancreatitis. Most APFC remain 
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sterile and resolve spontaneously without intervention, they 
do not by themselves constitute severe acute pancreatitis [3]. 
Pancreatic pseudocysts are peri-pancreatic fluid collections 
surrounded by a well-defined wall with no solid material and 
markedly increased amylase activity. A pancreatic pseudo-
cyst usually arises after more than 4 weeks of the start of an 
attack and are nearly always associated with chronic pan-
creatitis. A pseudocyst is extremely rare in acute pancreatitis 
and use of the term pancreatic pseudocyst in the setting of 
acute pancreatitis may fall into disuse [3]. A pseudocyst may 
occur in acute necrotising pancreatitis secondary to a dis-
rupted main pancreatic duct, whereby parenchymal necrosis 
of the neck or body isolates a viable distal remnant [3, 4].
Acute necrotising pancreatitis may feature acute 
necrotic collections (ANC), which have mixed heterogene-
ous contents with no definable wall or capsule. Walled-off 
necrosis (WON), which may be intrapancreatic or extra-
pancreatic, has mixed fluid and solid components as well 
as a defined capsule and requires at least 4 weeks follow-
ing the onset of necrotising pancreatitis to mature [3].
Although many PFCs will resolve spontaneously, inter-
vention is indicated in cases when infection is present or if 
the collection is persistently symptomatic [3, 5]. Manage-
ment options for PFCs include percutaneous, endoscopic, 
minimal access and open surgical techniques [6–8]. A 
recent randomised trial has shown equal efficacy between 
surgery and endoscopic drainage of pseudocysts but found 
reduced length of hospital stay and reduced costs for endo-
scopic intervention [9]. Thus, endoscopic management is 
now often regarded as first-line management of PFCs with 
multiple studies demonstrating its safety and high success 
rates [10, 11].
Endoscopic drainage of PFCs traditionally involves 
creating a fistula and placement of plastic stents to enable 
resolution by transluminal drainage. Natural progression 
led to the use of fully covered self-expanding metal stents 
(FCSEMS), initially designed for biliary stenting and 
latterly specifically designed FCSEMS as well as lumen 
apposing metal stents (LAMS) [10, 12]. Metal stents have 
the advantage of large diameter lumens, which facili-
tate better drainage, particularly when there is debris or 
necrotic tissue present. They also allow easy and safe 
access to the cavity for direct endoscopic necrosectomy if 
required [13]. However, metal stents are significantly more 
expensive than plastic stents and some early reports raised 
safety concerns regarding their use, notably delayed bleed-
ing and embedded stents [14]. With high success rates 
using plastic stents published, some centres do not see the 
benefit of metal stents, particularly for pseudocyst drain-
age [10].
A systematic review published in 2015 concluded that 
there was no evidence to support the routine use of metal 
stents for drainage of pancreatic fluid collections [15]. Since 
then, however, several studies comparing plastic double pig-
tail stents and FCSEMS/LAMS have been published in the 
literature.
The aim of this systematic review and meta-analysis is 
to review these recently published studies to assess clini-
cal success rates, adverse events and requirement of further 
intervention, when treating PFC of any description.
Materials and methods
Eligibility criteria
The inclusion criteria for qualitative and quantitative analy-
sis were comparative studies between plastic double pig-
tail stents and metal stents for drainage of both walled-off 
necrosis (WON) and pseudocysts. Randomised controlled 
trials, prospective and retrospective studies were all eli-
gible for inclusion as preliminary searches demonstrated 
few randomised controlled trials. Studies that used LAMS, 
FCSEMS and biliary self-expanding metal stents were all 
included. Only English language adult studies were included. 
No date criteria were set. The review was conducted accord-
ing to the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) [16] and the protocol was reg-
istered on PROSPERO (http://www.crd.york.ac.uk/PROSP 
ERO, CRD42017071101).
Information sources
MEDLINE, Pubmed and SCOPUS databases were searched, 
with the final search conducted on 20/10/17. References of 
included studies were also screened.
Search
The search terms were “pseudocyst” OR “pancreatic fluid 
collection” OR “walled-off necrosis” AND “endoscopy” OR 
“endoscopic ultrasound” OR “EUS” AND “stent”.
Study selection
Search results were combined on the Covidence software 
platform. Duplicate records were removed. Two reviewers 
(RSa, JR) independently scanned the title and abstract of all 
records identified during the search. Full-text articles were 
retrieved and reviewed if it was not clear from the abstract if 
inclusion criteria were met. We included studies irrespective 
of whether they reported all outcome measures. Studies not 
meeting the inclusion criteria were excluded with the reason 
for exclusion recorded.
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Data collection process
Data were extracted independently in a standardised table 
by two reviewers (RSa, SC). Agreement was reached by 
consensus.
Data items
The following characteristics were extracted from the stud-
ies: study design, number of centres, location of centres, date 
of studies, total number of participants, mean age, sex, type 
of PFC, type of metal stent, type and number of plastic stent, 
follow-up period and size of PFC.
The primary outcome measure recorded was clinical 
success, defined as resolution of pancreatic fluid collection. 
Secondary outcome measures were adverse events and rate 
of reintervention. Other outcomes recorded were technical 
success, recurrence, length of stay and stent migration.
Statistics
Random effects modelling was undertaken for each of the 
outcomes of interest. The effect size between metal and plas-
tic stents was described in terms of individual and pooled 
risk ratios with 95% confidence intervals and weighting 
estimated using the Mantel–Haenszel method. Forest plots 
were generated and study heterogeneity was investigated 
using the I2 statistic. An I2 exceeding 50% was considered 
to indicate significant heterogeneity. Sensitivity analyses 
were performed on the outcomes when heterogeneity or out-
lier studies were found. The effect size between metal and 
plastic stents was also explored for pseudocyst and WON 
separately. Funnel plots were used to explore the presence 
of publication bias and Egger’s regression test for assess-
ing their asymmetry. We considered p values < 0.05 to be 
statistically significant. All the analyses were performed in 
Stata 14 (StataCorp, College Station, Texas, USA), using 
the command Metan for fitting random effects models and 
producing forest plots.
Results
Study selection
The database search returned 1768 articles, 936 remained 
after duplicates were removed (see Fig. 1). Twelve full-text 
articles were reviewed and five were excluded; four were not 
comparative studies and another was from the same centre 
as an included study [17, 18] and it was unclear if the data 
were duplicated. Seven studies were included in the analysis 
[17, 19–24]. It is important to state that patient allocation to 
study group was by stent, rather than by type of pancreatic 
fluid collection.
Study characteristics
The characteristics of included studies are shown in Table 1. 
Patient demographic information and characteristics are 
summarised in Table 2. The outcome measures of individual 
studies are summarised in Table 3.
Synthesis of results
Clinical success
The results for the primary outcome measure of clinical 
success are shown in Fig. 2. The seven papers included in 
this analysis contained a total of 681 patients, 340 and 341 
had metal and plastic stents, respectively. Overall, 93.8% 
of patients in the metal stent group and 86.2% in the plastic 
stent group achieved clinical success. The pooled risk ratio 
(RR) suggests an increase in clinical success when metal 
stents are used compared to plastic stents (1.08 [95% CI 
1.02–1.14], p = 0.009; I2 = 25.4%).
There was heterogeneity of definition of clinical suc-
cess between studies, summarised in Table 4. Five studies 
defined success using both radiological and clinical crite-
ria. One study assessed clinical improvement only and one 
study reported radiological resolution. For the Ang et al., we 
included final clinical success for the quantitative analysis, 
for Dayyeh et al., we included the results that regarded con-
comitant percutaneous drainage as a failure of endoscopic 
drainage for better consistency across studies.
Subgroup analysis was undertaken and found four studies 
specific for WON, comprising 186 and 150 for metal and 
plastic stent groups, respectively (see Fig. 3). Only two stud-
ies were suitable for analysis for pseudocysts, including 119 
patients with metal and 132 with plastic stents. For WON, 
clinical success was achieved in 91.4% of the metal stent 
group and 80.7% of patients with plastic stents. The pooled 
risk ratio suggests superiority of metal stents but does not 
reach significance (1.11 [95% CI 0.98–1.24], p = 0.089; 
I2 = 48.6%). Similarly, clinical success in the pseudocyst 
group occurred in 98.3% of those patients with metal stents 
and 89.4% of those with plastic stents. The pooled risk ratio 
(1.10 [95%CI 1.03–1.17], p = 0.005; I2 = 0.0%) suggests 
placing metal stents increases clinical success in patients 
with a pseudocyst, however, interpretation is limited due to 
the small number of studies included.
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Adverse events
The adverse events reported in individual studies are sum-
marised in Table 5. A total of 592 patients from six studies 
were considered for this analysis; 284 in the metal and 308 
in the plastic stent group (see Fig. 4). Adverse events were 
noted in 10.2% of the metal and 25.0% in plastic stent group. 
The pooled risk ratio demonstrated a 58% reduced risk of 
Fig. 1  PRISMA flow chart of 
search [16]
Table 1  Characteristics of included studies
*In Lee et al., five patients were lost to follow-up (3 and 2 in plastic and metal stents, respectively). Therefore, the number of patients used for 
calculating clinical success, reintervention and recurrence was 45 (22/23)
Author Year Study type Number of patients (%) PFC type (%) Metal stent type 
(diameter mm)
Plastic stent size 
(number of stents)Plastic stent Metal stent Pseudocyst WON
Ang et al. 2016 [24] Retrospective 2 centre 37 (76) 12 (24) 31 (63) 18 (37) Nagi (16 mm) (1–2)
Bang et al. 2016 [19] Retrospective case 
control
40 (67) 20 (33) 21 (35) 39 (65) Hot AXIOS (15 mm) 7f 4 cm (2)
Bapaye et al. 2016 
[20]
Retrospective 61 (46) 72 (54) – 133 (100) Nagi (16 mm) 7f (2–4)
Dayyeh et al 2017 
[23]
Retrospective 36 (38) 58 (62) – 94 (100) Axios (15 mm), Niti-s 
(18 or 20 mm)
7f or 10f (2 or more)
Lee et al. 2014 [22] *RCT 25 (50) 25 (50) 14 (28) 36 (72) BONA-Soo (8 mm) 7f (2–3)
Mukai et al. 2014 [21] Retrospective 27 (39) 43 (61) – 70 (100) Axios (10 or 15 mm) 
Niti-s (16 mm) 
Hanaro (12 mm)
7f (1–2)
Shariaha et al 2015 
[24]
Retrospective 2 centre 
cohort
118 (51) 112 (49) 230 (100) – Wallflex Gore Viabl 
(10 mm)
10f (2)
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experiencing adverse events when a metal stent was used 
compared to plastic (0.42 [95% CI 0.22–0.81], p = 0.010; 
I2 = 42.9%). Results from Dayyeh et al. were not included as 
the summaries were reported for each adverse event sepa-
rately. Random effects models for stent migration and perfo-
ration were fitted, however, no significant effect size between 
the two types of stents was identified.
The outcome of bleeding was analysed separately (see 
Fig. 5). The six papers included in the analysis contained a 
total of 626 patients, 322 of which treated with metal stents 
and 304 with plastic stents. Bleeding was reported for 2.8% 
and 7.9% of patients treated with metal and plastic stents, 
respectively. The pooled Risk Ratio indicates that the use 
of metal stents reduced the risk of bleeding by 63% com-
pared to plastic stents (0.37; [95% CI 0.18–0.75], p = 0.006; 
I2 = 0.0%). The results do not show heterogeneity, suggesting 
bleeding risk was consistent across the publications. Results 
from Bang et al. were not included as it does not specifically 
report bleeding adverse events.
Subgroup analysis was undertaken and found three 
studies reporting adverse events for WON separately and 
were included in the analysis, 128 patients had metal stents 
included and 114 for plastic (see Fig. 6). Adverse events 
occurred in 8.6% of patients with metal stents and 26.3% of 
the plastic stent group. The pooled risk ratio (0.52 [95%CI 
0.10–2.79], p = 0.442; I2 = 82.4%) does not suggest a signifi-
cant reduction in adverse events for either plastic or metal 
stents for patients with WON. Two studies with 119 and 
132 patients with metal and plastic stents, respectively, were 
likewise reported for pseudocysts. Adverse events occurred 
in 15.1% of patients with metal stents and 30.3% of those 
with plastic stents. The pooled risk ratio (0.50 [0.31–0.82], 
p = 0.006; I2 = 0.0%) suggests that inserting a metal stent 
reduced the risk of experiencing an adverse event in patients 
with pseudocysts.
The infection rate post stent insertion for metal stents 
was 5.4% and 13.2% for plastic stents. The pooled risk 
ratio (0.53 [95% CI 0.23–1.20], p = 0.127; I2 = 41.9%) 
does not suggest a difference between the groups. The 
severity of post-procedural infection was not well defined 
within the studies [17, 24]. One study reported a single 
mortality from uncontrolled sepsis [21], another reported 
2/58 (3%) of metal 2/36 and (6%) of plastic stent patients 
required transfer to intensive care for sepsis management 
[23]. In three studies, either surgical or endoscopic inter-
vention was required for control of infection [19, 20, 22]. 
Bang et al. stated 3/20 (15%) and 5/40 (12.5%) patients 
in the metal and plastic groups, respectively, developed 
post-procedural infection, four patients were managed 
with further endoscopic procedures and three by surgi-
cal techniques but this is not specified by stent type [19]. 
Bapaye et al. reported 2/72 (2.8%) patients with metal 
and 16/61 (26.2%) with plastic stents developed infection Ta
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Table 3  Summary table of outcome measures
*Dayyeh et al. summarised median length of stay
Author
Year
Technical suc-
cess (%)
Clinical success 
(%)
Adverse events (%) PFC recurrence 
(%)
Reintervention 
(%)
Mean length of 
stay (days)
Plastic Metal Plastic Metal Plastic Metal Plastic Metal Plastic Metal Plastic Metal
Ang et al. 2016 [24] 100.0 100.0 94.6 100.0 13.5 0.0 – 35.1 8.3 –
Bang et al. 2016 [19] 100.0 100.0 92.5 95.0 15.0 20.0 0.0 0.0 30.0 25.0 9.2 9.3
Bapaye et al. 2016 [20] 100.0 100.0 73.8 94.4 36.1 5.6 0.0 0.0 26.2 2.8 8.0 4.1
Dayyeh et al 2017 [23] – 75.0 82.8 Summaries of specific AE 
presented
– – 8.0* 4.0*
Lee et al. 2014 [22] 100.0 100.0 90.9 87.0 8.0 0.0 0.0 4.5 9.1 13.0 –
Mukai et al. 2014 [21] 100.0 100.0 92.6 97.7 18.5 7.0 – 25.9 23.3 28.7 22.5
Sharaiha et al. 2015 [17] 92.0 98.0 89.0 98.2 31.4 16.1 3.4 0.9 – –
Fig. 2  Forest plot for individual and pooled risk ratio of clinical success
Table 4  Definitions of clinical success
Author
Year
Definition clinical success
Ang et al. 2016 [24] Size < 2 cm on imaging and resolution of symptoms
Bang et al. 2016 [19] Size < 2 cm on imaging with resolution of symptoms at 8 weeks
Bapaye et al. 2016 [20] Symptom resolution and complete resolution on imaging at end of treatment period
Dayyeh et al. 2017 [23] Complete clinical amelioration of acute index symptoms and resolution on imaging
Lee et al. 2014 [22] Size < 2 cm on CT performed every 4 weeks with resolution of symptoms
Mukai et al. 2014 [21] Resolution of symptoms
Sharaiha et al. 2015 [17] Resolution at 12 months on imaging
Surgical Endoscopy 
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Fig. 3  Forest plot showing individual and pooled risk ratios of clinical success for pseudocysts and walled-off necrosis
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that were all managed surgically [20]. In the study by Lee, 
2/25 (8%) of metal and 3/25 (12%) of the plastic group 
were found to have post-procedural infection and were all 
managed with further endoscopic drainage [22].
Reintervention
Reintervention data were available from five studies (see 
Fig. 7), therefore the analysis contains 357 patients, 170 
and 187 in metal and plastic stent groups, respectively. The 
percentage of patients requiring reintervention was 12.4% 
among those treated with metal stent and 26.7% in the plas-
tic stent group. The pooled risk ratio suggests a higher risk 
of reintervention when plastic stent were used, however, 
treatment effect failed to reach statistical significance (0.54; 
[95% CI 0.22–1.29], p = 0.165; I2 = 59.6%).
The stated definitions for reintervention were a need 
for repeat endoscopy or surgery due to persistent symp-
toms associated with residual PFC that had not reduced by 
> 50% in size [24], if symptoms or inflammation continued 
despite drainage and additional sessions of direct endoscopic 
necrosectomy [21], additional transmural drainage and/or 
Table 5  Frequency of specific adverse events
*Ang et al. reports stent migration for stent cross-over
Author
year
Bleeding (%) Stent migration (%) Infection (%) Perforation (%) Tract dilatation (%)
Plastic Metal Plastic Metal Plastic Metal Plastic Metal Plastic metal
Ang et al. 2016 [24] 5.4 0.0 Cross-over of stent summary 
presented*
2.7 0.0 2.7 0.0 8.0 8.0
Bang et al. 2016 [19] – 2.5 10.0 12.5 15.0 – 12.0–15.0 –
Bapaye et al. 2016 [20] 8.2 2.8 3.3 2.8 26.2 2.8 – 18.0 6.0
Dayyeh et al. 2017 [23] 19.4 6.9 19.4 20.7 5.6 3.4 8.3 1.7 15.0–18.0 15.0–18.0
Lee et al. 2014 [22] 4.0 0.0 4.0 0.0 8.0 12.0 – 8.0 When 
resistance 
encountered
Mukai et al. 2014 [21] 11.1 0.0 3.7 4.7 – 0.0 2.3 15.0–20.0 –
Sharaiha et al. 2015 [17] 5.1 2.7 0.8 0.9 13.6 5.4 4.2 1.8 10.0 10.0
Fig. 4  Forest plot for individual and pooled risk ratio of adverse events
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endoscopic necrosectomy [19] and salvage surgical inter-
vention [20].
Sharaiha et al. and Dayyeh et al. were not included as 
reintervention rates were not reported fully. Sharaiha et al. 
stated that 52 (22%) patients required further interventions 
for pseudocysts within first month. Furthermore, it reported 
a significant difference in short-term intervention (p = 0.008) 
but does not include actual numbers or clarify which stent 
was superior [17].
Subgroup analysis was undertaken and found three studies 
specified reintervention in WON (see Fig. 8). 128 and 114 
patients had metal and plastic stents inserted, respectively. 
21.1% of those in the metal group and 22.9% in the plastic 
group required reintervention. The pooled risk ratio (0.65 
[95% CI 0.16–2.60], p = 0.543; I2 = 84.8%) does not suggest 
a superiority for either stent. Only one study was suitable for 
inclusion in the pseudocyst analysis so meta-analysis was 
unable to be performed.
Publication bias, subgroup and sensitivity analyses
The Bapaye study was a consistent outlier in the quantitative 
analysis. Sensitivity analyses performed without this study, 
confirmed the same findings of the main analyses and showed 
a considerable drop in heterogeneity. There was no significant 
difference in methodology or reporting to explain this and no 
reason to exclude it from the analysis.
Funnel plots to assess publication bias for outcomes are 
presented in supplementary information. The graphs do not 
reflect any publication bias and Egger’s regression tests for 
asymmetry yielded statistically non-significant p-values.
Discussion
This meta-analysis demonstrates superior clinical suc-
cess and reduced adverse events for use of metal stents 
when compared to plastic for endoscopic transluminal 
drainage of pancreatic fluid collections. Previous meta-
analysis by Bang et al. showed no difference in the efficacy 
and adverse events between plastic and metal stents for 
Fig. 5  Forest plot for individual and pooled risk ratio of bleeding
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drainage of PFCs [15]. The majority of these data were 
derived from the use of specifically designed, large calibre, 
covered metal stents with lumen apposing flanges, unlike 
the previous review. It is likely that the improved outcomes 
Fig. 6  Forest plot showing individual and pooled risk ratios for adverse events for pseudocysts and walled-off necrosis
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of metal stents in this review are as a result of these stents 
as they are tailored for PFC drainage.
The fistula created by balloon dilatation enables plastic 
stent placement and drainage of fluid, however, this may 
be insufficient due to spontaneous closure of the fistula 
around the stent. Plastic stents have substantially smaller 
lumens than metal stents leaving them more susceptible 
to blockage or occlusion, even in pseudocysts or WON 
Fig. 7  Forest plot for individual and pooled risk ratio for reintervention
Fig. 8  Forest plot showing individual and pooled risk ratios for reintervention in walled-off necrosis
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with minimal debris. Although the use of plastic or metal 
stents was not found to reduce infection post drainage, 
metal stents can facilitate drainage of both liquid and the 
viscous necrotic debris, leading to the higher rates of suc-
cessful drainage. Patients are not always routinely inves-
tigated by EUS prior to intervention; this is reflected in 
these studies where PFC’s were frequently diagnosed by 
CT or MR imaging. CT imaging has a low sensitivity for 
assessing necrosis so there is diagnostic uncertainty when 
judging a collection to be a pseudocyst or WON. Recent 
guidance suggests that MRI or ultrasound assessment may 
be required to accurately characterise the collection [3].
There are several limitations of this systematic review 
and meta-analysis. All but one included studies are retro-
spective studies with the inherent bias associated with this 
methodology [17, 19–23]. There was a discrepancy in type 
and quality of included studies leading to the synthesis of 
results of variable reliability [25, 26]. There were also dif-
ferences between definitions for the outcomes reported. Dif-
ferent types of metal stent were used both in individual and 
across studies; it is not currently clear in published literature 
if there is any demonstrable clinical advantage of a particular 
stent. In two studies there is a discrete time point where prac-
tice changed and metal stents were used routinely; however, 
in four studies, plastic stents continued to be used for PFCs 
with certain characteristics leading to conceivable selection 
bias [21]. Furthermore, the sample sizes of some studies 
are relatively small and correspond to extended periods of 
time. The number of studies included in the meta-analyses 
is also quite limited and therefore meta-regression was not 
performed for exploring further the cause of heterogeneity.
All these studies were designed to investigate a difference 
in outcomes between stents not between types of PFC. There 
are limitations in combining pseudocysts and WON for data 
analysis and potential limitations in the classification of PFC 
within individual studies. The revised Atlanta criteria were 
introduced in 2012, therefore it is likely that patients were 
classified differently over the period the studies were ongo-
ing. However, in the studies included except for Mukai et al. 
[21], patients have short or no length of stay recorded and 
no clinical details suggesting these are not acutely unwell 
patients with infected pancreatic necrosis but rather patients 
being treated on a semi-elective basis. The subgroup analy-
ses for drainage of pseudocysts in terms of clinical success 
and adverse events suggest that metal stents remain advanta-
geous over that of plastic stents. Similar subgroup analyses 
for drainage of WON with metal stents are less convinc-
ing, with clinical success almost reaching significance, 
while adverse events or reintervention show no difference 
between metal or plastic stents. However, these subgroup 
analyses are limited by the very small numbers of studies 
which state these indications separately and therefore it is 
difficult to draw conclusions based on these data. Finally, the 
cost incurred was not evaluated in this analysis.
Our analysis showed that patients were 58% less likely to 
experience an adverse event with metal compared to plastic 
stents. Inserting plastic stents, particularly multiple plastic 
stents can be technically demanding and time consuming 
which may in part explain the increased risk [22]. Bleeding 
was significantly more common in patients with a plastic 
stent (2.8 vs. 7.9%, p = 0.006), this may be due to the greater 
dilatation required for plastic stent insertion. Dilatation of 
the tract prior to stent insertion for plastic stents ranged from 
8 to 20 mm and 0–18 mm for metal stents in studies included 
in this review. The majority of studies used multiple plastic 
stents inserted, which has previously been shown to improve 
treatment success compared to using a single stent [27].
Delayed bleeding in patients with metal stents was 
reported in one study [20]. An interim analysis for a ran-
domised control trial by Bang et al. also reported signifi-
cant delayed bleeding in 3 of 12 patients with LAMS [14]. 
This required a change in the trial protocol to remove stents 
earlier than initially planned. Investigators described bur-
ied stent syndrome in 2/12 patients and 1/12 patient with 
a biliary stricture secondary to a stent [14]. However, high 
rates of adverse events have not been seen in other cohorts 
of patients with LAMS [28]. The experience with LAMS 
is still early and more multicentre, prospective randomised 
data are required to accurately quantity the risk; elucidate 
causes for the risk and suggest potential solutions. It is likely 
that the delayed bleeding and buried stent problems seen 
with LAMS are due to its design rather than procedural steps 
in stent insertion.
There was no significant difference in the rate of reinter-
vention between plastic and metal stents. This could be due 
to type 2 error as two of the largest studies were not included 
in the analysis and it was a relatively rare event for the sam-
ple size. Reported reintervention rates ranged from 2.8 to 
35.1% between studies. The type of reintervention required 
also varied and was not always specified by authors. Bapaye 
et al. stated that salvage surgery was required in 26.2% of 
patients with plastic stents; however, Mukai et al. reported 
no patients required surgical intervention for inadequate 
drainage. This may suggest heterogeneity between included 
patients or difference in practice between centres.
EUS-guided drainage is regarded as first-line treatment 
for pancreatic fluid collections requiring intervention. The 
use of transmural metal stents increases the probability of 
clinical success and reduces the frequency of adverse events 
when compared to plastic stents for EUS-guided drainage 
of pancreatic fluid collections. Future, well-designed pro-
spective randomised control trials with multiple centres are 
required to evaluate clinical outcomes, adverse events and 
potential costs.
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